Pacira Pharmaceuticals (PCRX) Price Target Raised to $126 at Goldman Sachs (Earlier)
Tweet Send to a Friend
Goldman Sachs earlier maintained a Buy rating on Pacira Pharmaceuticals (NASDAQ: PCRX) and raised its price target to $126.00 (from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE